Mankind Pharma's shares surged by 6% after reporting a 29% rise in Q2 profits, reaching ₹658.88 crore. The company attributed this growth to sales volume recovery, particularly in the chronic segment and domestic sales. Exports also saw a significant 57% increase. Motilal Oswal raised its target price on the stock, citing the company's strong growth prospects.
